戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nis consistent with clinical stage 3 partial androgen insensitivity.
2  presence of ambiguous genitalia and partial androgen insensitivity.
3 ript levels in a mouse model for conditional androgen insensitivity.
4  recurrence after radical prostatectomy, and androgen insensitivity.
5 issense mutation, R405S, that caused partial androgen insensitivity.
6 of three patients exhibiting either complete androgen insensitivity (CAI) or a contiguous gene syndro
7 ant prostate cancer in man and indicate that androgen insensitivity can be an inherent property of me
8 ctivation may eventually lead to the partial androgen insensitivity during the development of Kennedy
9 yed accelerated neurodegeneration and severe androgen insensitivity in comparison to AR100 littermate
10 e in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors.
11  of the FGF-R2(111b) isoform correlated with androgen insensitivity in these human prostate cancer mo
12                             Signs of partial androgen insensitivity, including testicular atrophy and
13 ain mutations that cause partial or complete androgen insensitivity into fusion proteins containing t
14  neuron degeneration accompanied by signs of androgen insensitivity, such as gynecomastia and reduced
15                                          905 androgen insensitivity syndrome (AIS)-associated loss-of
16 turally occurring mutations in families with androgen insensitivity syndrome (AIS).
17             Moreover, AR mutants in complete androgen insensitivity syndrome (CAIS) tend to have a gr
18 estes, including from patients with complete androgen insensitivity syndrome (CAIS).
19                                      Partial androgen insensitivity syndrome (PAIS) is caused by defe
20 em may be interrupted in a subset of partial androgen insensitivity syndrome (PAIS) patients.
21 ociated with a variety of diseases including androgen insensitivity syndrome and prostate cancer, but
22 is involved in various conditions, including androgen insensitivity syndrome and prostate cancer.
23 allosteric surfaces which are compromised in androgen insensitivity syndrome and reinforced by AR's o
24  Almost all AR missense mutations that cause androgen insensitivity syndrome are located in the highl
25 nar describes the clinical manifestations of androgen insensitivity syndrome from infancy to adulthoo
26                                              Androgen insensitivity syndrome in its complete form is
27 R mutations associated with oligospermia and androgen insensitivity syndrome map to Pro-390, the cons
28                                Management of androgen insensitivity syndrome should be undertaken by
29                                       In the androgen insensitivity syndrome, germ line AR mutations
30 iagnosed with XY ambiguous genitalia/partial androgen insensitivity syndrome, who was found to have a
31  target for mutations in prostate cancer and androgen insensitivity syndrome.
32 alia by disrupting AR function in males with androgen insensitivity syndrome.
33 , by utilizing mutations associated with the androgen insensitivity syndrome: Pro767Ala, Phe765Leu, M
34 bdominal gonads may be left through puberty (androgen insensitivity syndromes).
35 hed fertility, and systemic signs of partial androgen insensitivity that occur in Kennedy disease pat